BIOMAT Database Logo BIOMAT Database Logo

Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. 2003

Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Reproductive Endocrinology Center, University of Bologna, Bologna, Italy. marco.filicori@unibo.it

OBJECTIVE To carefully examine the features of controlled ovarian stimulation performed with recombinant FSH-alpha or hMG. METHODS Controlled, prospective, randomized comparison of fixed gonadotropin regimens. METHODS Academic research institution. METHODS Fifty infertile patients who were candidates for IUI. METHODS Patients were randomized to receive a fixed regimen of recombinant FSH-alpha (150 IU/day, 25 patients) or hMG (150 IU/day, 25 patients), after GnRH-agonist suppression (long regimen). METHODS Daily measurements of serum LH, immunoreactive FSH, hCG, E(2), P, and T. Transvaginal pelvic ultrasound every 2 days. Pregnancy and abortion rates. Cost of medications. Two recombinant FSH-alpha-treated patients did not respond. Despite matched daily FSH dose, duration of treatment (hMG 10.8 +/- 0.4 vs. recombinant FSH-alpha 12.4 +/- 0.5 days), gonadotropin dose (21.7 +/- 0.8 vs. 25.3 +/- 1.3 ampoules), gonadotropin cost (288 +/- 10 vs. 1,299 +/- 66 /cycle), serum P levels, and small preovulatory follicle number were significantly lower, and LH, hCG, immunoreactive FSH levels, and larger follicles on day 8 were significantly higher in hMG-treated patients. The pregnancy, abortion, and twin pregnancy rates did not differ. CONCLUSIONS The hMG administration was associated with: [1]. increased serum LH activity and immunoreactive FSH levels during treatment; [2]. reduced signs of premature luteinization; [3]. differential modulation of folliculogenesis; [4]. lower treatment duration, gonadotropin dose, and cost; and [5]. clinical outcome comparable to recombinant FSH-alpha.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008596 Menotropins Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations. Gonadotropins, Human Menopausal,Human Menopausal Gonadotropin,CP-89044,CP-90033,HMG Ferring,HMG Lepori,HMG Massone,Humegon,Menogon,Menopur,Menotrophin,Normegon,ORG-31338,Pergonal,Pergonal-500,CP 89044,CP 90033,CP89044,CP90033,Gonadotropin, Human Menopausal,Human Menopausal Gonadotropins,Lepori, HMG,Menopausal Gonadotropin, Human,ORG 31338,ORG31338,Pergonal 500,Pergonal500
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003338 Corpus Luteum The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE. Corpora Lutea,Lutea, Corpora
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome.
March 1990, Fertility and sterility,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles.
November 2003, Fertility and sterility,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles.
January 2000, The Cochrane database of systematic reviews,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles.
January 2003, The Cochrane database of systematic reviews,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Comparison of the combination of recombinant follicle-stimulating hormone and recombinant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis.
August 2020, Journal of evidence-based medicine,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Recombinant human follicle-stimulating hormone versus urinary-derived human menopausal gonadotropin for controlled ovarian stimulation: the science and art of assisted reproductive technologies.
November 2003, Fertility and sterility,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
June 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome.
May 1990, Fertility and sterility,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin.
January 2014, Reproductive biology and endocrinology : RB&E,
Marco Filicori, and Graciela E Cognigni, and Patrizia Pocognoli, and Cristina Tabarelli, and Federica Ferlini, and Tiziana Perri, and Lodovico Parmegiani
WITHDRAWN: Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles.
April 1996, The Cochrane database of systematic reviews,
Copied contents to your clipboard!